Community Acquired Pneumonia Clinical Trial
Official title:
Epidemiology of Community Acquired Pneumonia in North Israel
Pneumonia in general and CAP in particular is considered as one of the most common bacterial
infections, associated with high rates of morbidity and mortality and is highly significant
economically since all respiratory infections, and pneumonia especially, cause about 80% of
antimicrobials use in the community. The high frequency of respiratory infections and the
excessive use of antimicrobials are major contributors to the development of pathogens
resistant to antimicrobials. In addition, in CAP almost all patients are treated
empirically, without identification of causing pathogen.
Aim of study: To identify common pathogens causing CAP in hospitalized patients in north
Israel.
Pneumonia in general and CAP in particular is considered as one of the most common bacterial
infections, associated with high rates of morbidity and mortality.
CAP is highly significant economically since all respiratory infections, and pneumonia
especially, cause about 80% of antimicrobials use in the community. The high frequency of
respiratory infections and the excessive use of antimicrobials are major contributors to the
development of pathogens resistant to antimicrobials. In addition, in CAP almost all
patients are treated empirically, without identification of causing pathogen.
CAP is divided to two principal groups: Bacterial CAP and Atypical CAP. Since pathogens are
different, treatment approach is also different. The main obstacle is absence of adequate
diagnostic immediate and cheap tools to enable identifying pathogen and hence treatment is
not always appropriate. Giving the right therapy at the right time is of major importance
since early start of correct treatment is linked to morbidity and mortality of patients. For
prescribing appropriate empiric therapy, knowing the epidemiology of CAP, i.e. the frequent
causing pathogens according to age groups and other demographic characteristics, is
essential.
Unfortunately, except one study conducted 10 years ago by Dr. Liberman from Soroka Medical
Center, there is no characteristic information regarding causing pathogens. Lacking this
data, might result in selecting inadequate treatment.
Material & Methods:
We should enroll about 300 patients hospitalized in Ha'Emek Medical Center with the
diagnosis of CAP, in order to make the study results statistically significant.
In addition to demographic and clinical data, following tests will be performed:
1. Blood cultures
2. Sputum
3. PCR - throat culture to the following pathogens:
- Mycoplasma pneumoniae
- Chlamydia pneumoniae
- Legionella
- Adenovirus
- Influenza A
- Influenza B
- RSV
- Metapneumovirus
- Parainfluenza
- Pneumococcal antigen in urine
;
Observational Model: Defined Population, Time Perspective: Longitudinal
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02559310 -
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
|
Phase 3 | |
Completed |
NCT01530763 -
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
|
Phase 2/Phase 3 | |
Completed |
NCT02517489 -
Community-Acquired Pneumonia : Evaluation of Corticosteroids
|
Phase 3 | |
Not yet recruiting |
NCT01937832 -
A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
|
Phase 3 | |
Completed |
NCT02454114 -
HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections
|
N/A | |
Completed |
NCT00653172 -
Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia
|
Phase 2 | |
Recruiting |
NCT02139163 -
Epidemiological Study on Community Acquired Pneumonia
|
||
Completed |
NCT03411824 -
Lung Ultrasound for Community-acquired Pneumonia Diagnosis in Emergency Medicine
|
||
Recruiting |
NCT06210282 -
The Effect of Focused Lung Ultrasonography on Antibiotic Prescribing in General Practice
|
N/A | |
Withdrawn |
NCT02269644 -
A P3 Comparator Trial in Community Acquired Bacterial Pneumonia
|
Phase 3 | |
Recruiting |
NCT01963442 -
Short Duration Treatment of Non-severe Community Acquired Pneumonia
|
Phase 2 | |
Terminated |
NCT00887276 -
Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
|
Phase 4 | |
Completed |
NCT00079885 -
Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
|
Phase 3 | |
Not yet recruiting |
NCT04158310 -
Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
|
||
Recruiting |
NCT02552342 -
Corticosteroid Therapy for Severe Community-Acquired Pneumonia
|
Phase 4 | |
Completed |
NCT02922387 -
Smoking Cessation Intervention in Respiratory Inpatients
|
Phase 4 | |
Completed |
NCT00467701 -
Community Acquired Pneumonia in Telemark and Ostfold
|
N/A | |
Completed |
NCT04198571 -
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
|
||
Completed |
NCT02107001 -
Lung Ultrasound in Pleuritic Chest Pain
|
N/A | |
Completed |
NCT01561885 -
Collaborative Healthcare Professionals Approach in Monitoring of Patient Centered Outcomes Through Pathways
|
N/A |